Vera Therapeutics Shares Slip After FDA Acceleration Announcement Despite Earlier Run-Up
Vera Therapeutics shares fell roughly 4.9% in morning trading despite the company and the FDA agreeing to an accelerated Phase 3 eGFR analysis that brings kidney function data into Q3 2026 and targets a supplemental BLA for Q4 2026. The pullback follows a prior rally and is consistent with profit-taking, as analysts left ratings unchanged and the c…